Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib

Gastrointestinal Stromal Tumors Clinical Trial

Official title:

An Open-label, Multi-center, Single-arm Study to Evaluate the Efficacy of Nilotinib in Adult Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line Treatment

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT00756509
• Other study ID #: CAMN107DDE06
• Secondary ID: 2008-000358-11
• Status: Active, not recruiting
• Phase: Phase 4
• Start date: August 29, 2008
• Est. completion date: December 31, 2024

Study information

• Verified date: March 2024
• Source: Novartis
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this multicenter, single-arm, exact binomial single-stage, phase II trial is to evaluate the efficacy of Nilotinib in patients with unresectable or metastatic gastrointestinal stromal tumors

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 34
• Est. completion date: December 31, 2024
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age =18 years

• Histologically confirmed diagnosis of GIST that is unresectable and/or metastatic and therefore not amenable to surgery or combined modality with curative intent prior to or at Visit 1

• At least one measurable site of disease on CT/MRI scan at Visit 1, as defined by RECIST criteria (see Post Text Suppl 3 for details) The scans should be at maximum 2 weeks old. New scans are only required as baseline scans if they are older then approx. 2 weeks.

• WHO Performance Status of 0, 1 or 2

• Patients must have the following laboratory values (= LLN (lower limit of normal) or corrected to within normal limits with supplements prior to the first dose of study medication.):

1. Potassium = LLN,

2. Magnesium = LLN,

3. Phosphorus = LLN,

4. Total calcium (corrected for serum albumin) = LLN

• Patients must have normal organ, electrolyte, and marrow function as defined below:

1. Absolute Neutrophil Count (ANC) = 1.5x 109/L;

2. Platelets = 100 x 109/L;

3. ALT and AST = 2.5 x upper limit of normal (ULN) or = 5.0 x ULN if considered due to tumor;

4. Alkaline phosphatase = 2.5 x ULN unless considered due to tumor;

5. Serum bilirubin = 1.5 x ULN;

6. Serum lipase and amylase = 1.5 x ULN;

7. Serum creatinine = 1.5 x ULN or 24-hour creatinine clearance = 50 ml/min. (calculated creatinine clearance using Cockroft formula is acceptable)

• Ability to understand and willingness to sign a written informed consent

Exclusion Criteria:

• Prior treatment with nilotinib

• Treatment with any cytotoxic and/or investigational cytotoxic drug = 4 weeks (6 weeks for nitrosurea or mitomycin C) prior to Visit 1 with the exception of imatinib targeted therapy as an adjuvant therapy

• Prior or concomitant malignancies requiring active treatment other than GIST with the exception of previous or concomitant basal cell skin cancer, previous cervical carcinoma in situ

• Impaired cardiac function at including any one of the following:

1. LVEF < 45% or below the institutional LLN range (whichever is higher) as determined by echocardiogram at Visit 1

2. Complete left bundle branch block

3. Use of a ventricular paced cardiac pacemaker

4. Congenital long QT syndrome or family history of long QT syndrome

5. History of or presence of significant ventricular or atrial tachyarrhythmias

6. Clinically significant resting bradycardia (< 50 beats per minute)

7. QTc > 450 msec on screening ECG (using the QTcF formula). If QTc > 450 msec and electrolytes are not within normal ranges (electrolytes should be corrected and then the patient rescreened for QTc.

8. Right bundle branch block plus left anterior hemiblock, bifascicular block

9. Myocardial infarction within 12 months prior to Visit 1

10. Other clinically significant heart disease (e.g., unstable angina, congestive heart failure or uncontrolled hypertension,)

• Patients with severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol e.g. impairment of gastrointestinal (GI) function, or GI disease that may significantly alter the absorption of the study drugs, uncontrolled diabetes

Related Conditions & MeSH terms

• Gastrointestinal Stromal Tumors

Intervention

Drug:
• Nilotinib
800 mg/d orally

Locations

Country	Name	City	State
Finland	Novartis Investigative Site	HUS
France	Novartis Investigative Site	Lyon
Germany	Novartis Investigative Site	Bad Saarow
Germany	Novartis Investigative Site	Essen
Germany	Novartis Investigative Site	Hannover
Germany	Novartis Investigative Site	Muenchen
Italy	Novartis Investigative Site	Milano	MI

Sponsors (1)

Lead Sponsor	Collaborator
Novartis Pharmaceuticals

Countries where clinical trial is conducted

Finland,  France,  Germany,  Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To evaluate the efficacy of Nilotinib in patients with unresectable or metastatic gastrointestinal stromal tumors. Efficacy is defined as the proportion of patients showing stable disease (SD), partial response (PR) or complete response (CR) during the		6 months
Secondary	objective tumor response rate based on RECIST criteria (complete response (CR) and partial response PR)		6 months
Secondary	time to overall response (PR or CR)		6 months
Secondary	duration of response		6 months
Secondary	progression free survival (PFS) during the first 6 months using RECIST criteria		6 months
Secondary	overall survival (OS)		6 months
Secondary	safety and tolerability		6 months
Secondary	population pharmacokinetics of Nilotinib		6 months